New mechanisms of multidrug resistance: an introduction to the Cancer Drug Resistance special collection [0.03%]
抗癌药物耐药性新机制介绍——《抗癌药物耐药性》特刊序言
Michael M Gottesman,Robert W Robey,Suresh V Ambudkar
Michael M Gottesman
Cancer Drug Resistance publishes contributions to understanding the biology and consequences of mechanisms that interfere with successful treatment of cancer. Since virtually all patients who die of metastatic cancer have multidrug-resistan...
Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment [0.03%]
肿瘤内在代谢重编程及其介导的抗PD-1 / PD-L1治疗抵抗机制研究
Kyra Laubach,Tolga Turan,Rebecca Mathew et al.
Kyra Laubach et al.
The development of immune checkpoint blockade (ICB) therapies has been instrumental in advancing the field of immunotherapy. Despite the prominence of these treatments, many patients exhibit primary or acquired resistance, rendering them in...
A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer [0.03%]
铁死亡在癌症中的机制及通路的最新研究进展及其对卵巢癌治疗策略的潜在影响的全面综述
Hiroshi Kobayashi,Chiharu Yoshimoto,Sho Matsubara et al.
Hiroshi Kobayashi et al.
Cancer cells adapt to environmental changes and alter their metabolic pathways to promote survival and proliferation. Metabolic reprogramming not only allows tumor cells to maintain a reduction-oxidation balance by rewiring resources for su...
Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena [0.03%]
肾细胞癌的新兴抵抗与免疫检查点抑制剂失应答：两种不同的现象
Arya Mariam Roy,Saby George
Arya Mariam Roy
The introduction of immune checkpoint inhibitor (ICI) has revolutionized the treatment of metastatic renal cell carcinoma (mRCC) and has dramatically improved the outcomes of patients. The use of monotherapy or combinations of ICIs targetin...
Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia [0.03%]
急性髓系白血病中T细胞逃避免疫检查点抑制剂的机制
Lindsay Gurska,Kira Gritsman
Lindsay Gurska
Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematologic malignancy that is associated with a high relapse rate and poor prognosis. Despite advances in immunotherapies in solid tumors and other hematologic malignancies, AM...
The multifaceted role of extracellular vesicles in prostate cancer-a review [0.03%]
外泌体在前列腺癌中的作用——综述
Divya Prakash Jain,Yirivinti Hayagreeva Dinakar,Hitesh Kumar et al.
Divya Prakash Jain et al.
Prostate cancer is the second most prominent form of cancer in men and confers the highest mortality after lung cancer. The term "extracellular vesicles" refers to minute endosomal-derived membrane microvesicles and it was demonstrated that...
A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer [0.03%]
应对免疫治疗前列腺癌免疫逃逸策略的评论研究论文
Kenneth Sooi,Robert Walsh,Nesaretnam Kumarakulasinghe et al.
Kenneth Sooi et al.
Immunotherapy has become integral in cancer therapeutics over the past two decades and is now part of standard-of-care treatment in multiple cancer types. While various biomarkers and pathway alterations such as dMMR, CDK12, and AR-V7 have ...
Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy [0.03%]
TCTP在乳腺癌治疗抵抗中的作用及个性化治疗机遇研究
Gianluca Santamaria,Mario Cioce,Antonia Rizzuto et al.
Gianluca Santamaria et al.
Early identification of breast cancer (BC) patients at a high risk of progression may aid in therapeutic and prognostic aims. This is especially true for metastatic disease, which is responsible for most cancer-related deaths. Growing evide...
Primary and acquired resistance to first-line therapy for clear cell renal cell carcinoma [0.03%]
一线治疗对透明细胞肾细胞癌的原发性和获得性耐药性
Serena Astore,Giulia Baciarello,Linda Cerbone et al.
Serena Astore et al.
The introduction of first-line combinations had improved the outcomes for metastatic renal cell carcinoma (mRCC) compared to sunitinib. However, some patients either have inherent resistance or develop resistance as a result of the treatmen...
Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells [0.03%]
他汀类药物可明显增强针对急性髓系白血病细胞的氨基肽酶抑制剂作用
Gerrit Jansen,Marjon Al,Yehuda G Assaraf et al.
Gerrit Jansen et al.
Aim: This study aimed to decipher the molecular mechanism underlying the synergistic effect of inhibitors of the mevalonate-cholesterol pathway (i.e., statins) and aminopeptidase inhibitors (APis) on APi-sensitive and -resistant acute myelo...